When it comes to the photographic image, rectilinearity is taken as a given — but it wasn’t for George Eastman, the founder ...

Merck Chief Commercial Officer Anand Nambiar spoke positively about Korea's unfaltering chip production capacity at a press ...

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

We recently published an article titled Jim Cramer Discusses These 10 Stocks & An Outfit Better Than DeepSeek. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands ...

In this piece, we will look at the stocks Jim Cramer recently discussed.

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Merck, with a 76.59% gross margin and $63.17 billion in revenue, continues expanding its global vaccine reach. Moreover, Merck announced a $0.81 quarterly dividend and a $10 billion stock buyback ...

HEIDELBERG, Germany, February 06, 2025 / Biotech Newswire / --German independent research institute BioMed X announces the successful completion of its oncology research project in partnership with ...

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $110.00. The company’s shares closed yesterday at $89.67.

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The company’s shares closed yesterday at $89.67. Leverage the ...